November 24th 2020
November 24, 2020 - Until now, the field of cell-based immunotherapy has been dominated by chimeric antigen receptor (CAR) T cells, with groundbreaking FDA approvals for 3 drugs across several types of hematologic malignancies. In solid tumors, however, CAR T-cell therapies have yet to gain ground.
November 17th 2020
The identification of chromosomal rearrangements that result in oncogenic gene fusions ushered in the era of molecularly targeted therapies in oncology.
October 8th 2020
Investigators are developing a new way to target a key oncogenic mechanism that may prove to be an effective anticancer strategy, particularly against hematologic malignancies.
September 15th 2020
TIGIT, an inhibitory immune checkpoint that plays a central role in limiting antitumor responses, is attracting robust interest in the research community as a novel target for combination therapies across a range of cancer types, particularly solid tumors.
September 3rd 2020
Precision medicine advancements are opening a new chapter in the development of anticancer therapies that target the HER2 pathway, resulting in 3 approvals for breast cancer in less than a year and raising hopes for attacking other cancer types.
August 21st 2020
Considerable efforts have focused on developing agonists of costimulatory receptors, including OX40.
August 5th 2020
Homologous recombination, one of the major mechanisms of defective DNA repair, has emerged as a bona fide therapeutic target, yet its optimal use as a biomarker for patient selection remains a clouded scientific question.
July 19th 2020
A novel compound that uses abundant lipids in cancer cell membranes to deliver a radioisotope to the tumor environment shows early signs of efficacy in a range of B-cell malignancies.
June 26th 2020
During the past 5 years, therapies targeting CD38, a protein highly expressed on the surface of plasma cells, have helped fuel the rapidly growing treatment options for patients with multiple myeloma.
June 8th 2020
Over the past decade, immunotherapy has established itself as one of the pillars of cancer treatment, thanks in large part to the success of monoclonal antibodies that target the immune checkpoint protein PD-1 or its main ligand, PD-L1.